As of 2025-01-21, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -0.60. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 106.73 mil USD. FATE's TTM EBITDA according to its financial statements is -176.53 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 16.2x | 16.0x |
| Forward P/E multiples | 16.3x - 21.8x | 18.9x |
| Fair Price | (24.87) - (24.72) | (26.72) |
| Upside | -2058.3% - -2046.1% | -2203.5% |
| Date | EV/EBITDA |
| 2025-01-17 | -0.60 |
| 2025-01-16 | -0.59 |
| 2025-01-15 | -0.64 |
| 2025-01-14 | -0.59 |
| 2025-01-13 | -0.62 |
| 2025-01-10 | -0.73 |
| 2025-01-08 | -0.86 |
| 2025-01-07 | -0.91 |
| 2025-01-06 | -0.99 |
| 2025-01-03 | -0.95 |
| 2025-01-02 | -0.94 |
| 2024-12-31 | -0.85 |
| 2024-12-30 | -0.83 |
| 2024-12-27 | -0.82 |
| 2024-12-26 | -0.83 |
| 2024-12-24 | -0.86 |
| 2024-12-23 | -0.86 |
| 2024-12-20 | -0.87 |
| 2024-12-19 | -0.86 |
| 2024-12-18 | -0.87 |
| 2024-12-17 | -1.00 |
| 2024-12-16 | -1.08 |
| 2024-12-13 | -0.97 |
| 2024-12-12 | -1.03 |
| 2024-12-11 | -1.19 |
| 2024-12-10 | -1.26 |
| 2024-12-09 | -1.54 |
| 2024-12-06 | -1.49 |
| 2024-12-05 | -1.32 |
| 2024-12-04 | -1.44 |
| 2024-12-03 | -1.48 |
| 2024-12-02 | -1.69 |
| 2024-11-29 | -1.83 |
| 2024-11-27 | -1.83 |
| 2024-11-26 | -1.51 |
| 2024-11-25 | -1.35 |
| 2024-11-22 | -1.26 |
| 2024-11-21 | -1.12 |
| 2024-11-20 | -1.22 |
| 2024-11-19 | -1.19 |
| 2024-11-18 | -1.25 |
| 2024-11-15 | -1.09 |
| 2024-11-14 | -1.13 |
| 2024-11-13 | -1.19 |
| 2024-11-12 | -1.32 |
| 2024-11-11 | -1.44 |
| 2024-11-08 | -1.35 |
| 2024-11-07 | -1.43 |
| 2024-11-06 | -1.59 |
| 2024-11-05 | -1.51 |